カテゴリー： Market Monitor Global, 世界, 医療/バイオ

虚血性心疾患治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Ischemic Heart Disease Drugs Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8525 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：74 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Ischemic Heart Disease Drugs Market 調査レポートは次の情報を含め、グローバルにおけるの虚血性心疾患治療薬市場規模と予測を収録しています。・世界の虚血性心疾患治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の虚血性心疾患治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の虚血性心疾患治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「狭心症」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

虚血性心疾患治療薬のグローバル主要企業は、AstraZeneca、 Actelion、 Bayer、 Boehringer Ingelheim、 Bristol-Myers Squibb、 Baxter、 Eli Lilly and Company、 Novartis、 Pfizer、 Sanofiなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、虚血性心疾患治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の虚血性心疾患治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の虚血性心疾患治療薬市場：タイプ別市場シェア、2022年
・狭心症、心筋梗塞

世界の虚血性心疾患治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の虚血性心疾患治療薬市場：用途別市場シェア、2022年
・抗脂質異常症薬、カルシウムチャネル遮断薬、β遮断薬、ACE阻害薬、ARB、血管拡張薬、抗血栓薬

世界の虚血性心疾患治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の虚血性心疾患治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における虚血性心疾患治療薬のグローバル売上、2018年-2023年
・主要企業における虚血性心疾患治療薬のグローバル売上シェア、2022年
・主要企業における虚血性心疾患治療薬のグローバル販売量、2018年-2023年
・主要企業における虚血性心疾患治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
AstraZeneca、 Actelion、 Bayer、 Boehringer Ingelheim、 Bristol-Myers Squibb、 Baxter、 Eli Lilly and Company、 Novartis、 Pfizer、 Sanofi

*************************************************************

・調査・分析レポートの概要
虚血性心疾患治療薬市場の定義
市場セグメント
世界の虚血性心疾患治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の虚血性心疾患治療薬市場規模
世界の虚血性心疾患治療薬市場規模：2022年 VS 2029年
世界の虚血性心疾患治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの虚血性心疾患治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の虚血性心疾患治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：狭心症、心筋梗塞
虚血性心疾患治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：抗脂質異常症薬、カルシウムチャネル遮断薬、β遮断薬、ACE阻害薬、ARB、血管拡張薬、抗血栓薬
虚血性心疾患治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別虚血性心疾患治療薬市場規模 2022年と2029年
地域別虚血性心疾患治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
AstraZeneca、 Actelion、 Bayer、 Boehringer Ingelheim、 Bristol-Myers Squibb、 Baxter、 Eli Lilly and Company、 Novartis、 Pfizer、 Sanofi
...

This report aims to provide a comprehensive presentation of the global market for Ischemic Heart Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ischemic Heart Disease Drugs. This report contains market size and forecasts of Ischemic Heart Disease Drugs in global, including the following market information:
Global Ischemic Heart Disease Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Ischemic Heart Disease Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Ischemic Heart Disease Drugs companies in 2022 (%)
The global Ischemic Heart Disease Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Angina Pectoris Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Ischemic Heart Disease Drugs include AstraZeneca, Actelion, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Baxter, Eli Lilly and Company, Novartis and Pfizer, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ischemic Heart Disease Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ischemic Heart Disease Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ischemic Heart Disease Drugs Market Segment Percentages, by Type, 2022 (%)
Angina Pectoris
Myocardial Infarction
Global Ischemic Heart Disease Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ischemic Heart Disease Drugs Market Segment Percentages, by Application, 2022 (%)
Anti-dyslipidemic Drugs
Calcium Channel Blockers
Beta-blockers
ACE Inhibitors
ARBs
Vasodilators
Antithrombotic Agents
Global Ischemic Heart Disease Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ischemic Heart Disease Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ischemic Heart Disease Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Ischemic Heart Disease Drugs revenues share in global market, 2022 (%)
Key companies Ischemic Heart Disease Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Ischemic Heart Disease Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Actelion
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Baxter
Eli Lilly and Company
Novartis
Pfizer
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Ischemic Heart Disease Drugs, market overview.
Chapter 2: Global Ischemic Heart Disease Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Ischemic Heart Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ischemic Heart Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Ischemic Heart Disease Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Ischemic Heart Disease Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Ischemic Heart Disease Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Ischemic Heart Disease Drugs Overall Market Size
2.1 Global Ischemic Heart Disease Drugs Market Size: 2022 VS 2029
2.2 Global Ischemic Heart Disease Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Ischemic Heart Disease Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Ischemic Heart Disease Drugs Players in Global Market
3.2 Top Global Ischemic Heart Disease Drugs Companies Ranked by Revenue
3.3 Global Ischemic Heart Disease Drugs Revenue by Companies
3.4 Global Ischemic Heart Disease Drugs Sales by Companies
3.5 Global Ischemic Heart Disease Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Ischemic Heart Disease Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Ischemic Heart Disease Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Ischemic Heart Disease Drugs Players in Global Market
3.8.1 List of Global Tier 1 Ischemic Heart Disease Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Ischemic Heart Disease Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Ischemic Heart Disease Drugs Market Size Markets, 2022 & 2029
4.1.2 Angina Pectoris
4.1.3 Myocardial Infarction
4.2 By Type – Global Ischemic Heart Disease Drugs Revenue & Forecasts
4.2.1 By Type – Global Ischemic Heart Disease Drugs Revenue, 2018-2023
4.2.2 By Type – Global Ischemic Heart Disease Drugs Revenue, 2024-2029
4.2.3 By Type – Global Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Ischemic Heart Disease Drugs Sales & Forecasts
4.3.1 By Type – Global Ischemic Heart Disease Drugs Sales, 2018-2023
4.3.2 By Type – Global Ischemic Heart Disease Drugs Sales, 2024-2029
4.3.3 By Type – Global Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Ischemic Heart Disease Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Ischemic Heart Disease Drugs Market Size, 2022 & 2029
5.1.2 Anti-dyslipidemic Drugs
5.1.3 Calcium Channel Blockers
5.1.4 Beta-blockers
5.1.5 ACE Inhibitors
5.1.6 ARBs
5.1.7 Vasodilators
5.1.8 Antithrombotic Agents
5.2 By Application – Global Ischemic Heart Disease Drugs Revenue & Forecasts
5.2.1 By Application – Global Ischemic Heart Disease Drugs Revenue, 2018-2023
5.2.2 By Application – Global Ischemic Heart Disease Drugs Revenue, 2024-2029
5.2.3 By Application – Global Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Ischemic Heart Disease Drugs Sales & Forecasts
5.3.1 By Application – Global Ischemic Heart Disease Drugs Sales, 2018-2023
5.3.2 By Application – Global Ischemic Heart Disease Drugs Sales, 2024-2029
5.3.3 By Application – Global Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Ischemic Heart Disease Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Ischemic Heart Disease Drugs Market Size, 2022 & 2029
6.2 By Region – Global Ischemic Heart Disease Drugs Revenue & Forecasts
6.2.1 By Region – Global Ischemic Heart Disease Drugs Revenue, 2018-2023
6.2.2 By Region – Global Ischemic Heart Disease Drugs Revenue, 2024-2029
6.2.3 By Region – Global Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Ischemic Heart Disease Drugs Sales & Forecasts
6.3.1 By Region – Global Ischemic Heart Disease Drugs Sales, 2018-2023
6.3.2 By Region – Global Ischemic Heart Disease Drugs Sales, 2024-2029
6.3.3 By Region – Global Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Ischemic Heart Disease Drugs Revenue, 2018-2029
6.4.2 By Country – North America Ischemic Heart Disease Drugs Sales, 2018-2029
6.4.3 US Ischemic Heart Disease Drugs Market Size, 2018-2029
6.4.4 Canada Ischemic Heart Disease Drugs Market Size, 2018-2029
6.4.5 Mexico Ischemic Heart Disease Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Ischemic Heart Disease Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Ischemic Heart Disease Drugs Sales, 2018-2029
6.5.3 Germany Ischemic Heart Disease Drugs Market Size, 2018-2029
6.5.4 France Ischemic Heart Disease Drugs Market Size, 2018-2029
6.5.5 U.K. Ischemic Heart Disease Drugs Market Size, 2018-2029
6.5.6 Italy Ischemic Heart Disease Drugs Market Size, 2018-2029
6.5.7 Russia Ischemic Heart Disease Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Ischemic Heart Disease Drugs Market Size, 2018-2029
6.5.9 Benelux Ischemic Heart Disease Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Ischemic Heart Disease Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Ischemic Heart Disease Drugs Sales, 2018-2029
6.6.3 China Ischemic Heart Disease Drugs Market Size, 2018-2029
6.6.4 Japan Ischemic Heart Disease Drugs Market Size, 2018-2029
6.6.5 South Korea Ischemic Heart Disease Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Ischemic Heart Disease Drugs Market Size, 2018-2029
6.6.7 India Ischemic Heart Disease Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Ischemic Heart Disease Drugs Revenue, 2018-2029
6.7.2 By Country – South America Ischemic Heart Disease Drugs Sales, 2018-2029
6.7.3 Brazil Ischemic Heart Disease Drugs Market Size, 2018-2029
6.7.4 Argentina Ischemic Heart Disease Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Ischemic Heart Disease Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Ischemic Heart Disease Drugs Sales, 2018-2029
6.8.3 Turkey Ischemic Heart Disease Drugs Market Size, 2018-2029
6.8.4 Israel Ischemic Heart Disease Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Ischemic Heart Disease Drugs Market Size, 2018-2029
6.8.6 UAE Ischemic Heart Disease Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Ischemic Heart Disease Drugs Major Product Offerings
7.1.4 AstraZeneca Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Actelion
7.2.1 Actelion Company Summary
7.2.2 Actelion Business Overview
7.2.3 Actelion Ischemic Heart Disease Drugs Major Product Offerings
7.2.4 Actelion Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Actelion Key News & Latest Developments
7.3 Bayer
7.3.1 Bayer Company Summary
7.3.2 Bayer Business Overview
7.3.3 Bayer Ischemic Heart Disease Drugs Major Product Offerings
7.3.4 Bayer Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Bayer Key News & Latest Developments
7.4 Boehringer Ingelheim
7.4.1 Boehringer Ingelheim Company Summary
7.4.2 Boehringer Ingelheim Business Overview
7.4.3 Boehringer Ingelheim Ischemic Heart Disease Drugs Major Product Offerings
7.4.4 Boehringer Ingelheim Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Boehringer Ingelheim Key News & Latest Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Ischemic Heart Disease Drugs Major Product Offerings
7.5.4 Bristol-Myers Squibb Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Bristol-Myers Squibb Key News & Latest Developments
7.6 Baxter
7.6.1 Baxter Company Summary
7.6.2 Baxter Business Overview
7.6.3 Baxter Ischemic Heart Disease Drugs Major Product Offerings
7.6.4 Baxter Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Baxter Key News & Latest Developments
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company Company Summary
7.7.2 Eli Lilly and Company Business Overview
7.7.3 Eli Lilly and Company Ischemic Heart Disease Drugs Major Product Offerings
7.7.4 Eli Lilly and Company Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Eli Lilly and Company Key News & Latest Developments
7.8 Novartis
7.8.1 Novartis Company Summary
7.8.2 Novartis Business Overview
7.8.3 Novartis Ischemic Heart Disease Drugs Major Product Offerings
7.8.4 Novartis Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Novartis Key News & Latest Developments
7.9 Pfizer
7.9.1 Pfizer Company Summary
7.9.2 Pfizer Business Overview
7.9.3 Pfizer Ischemic Heart Disease Drugs Major Product Offerings
7.9.4 Pfizer Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Pfizer Key News & Latest Developments
7.10 Sanofi
7.10.1 Sanofi Company Summary
7.10.2 Sanofi Business Overview
7.10.3 Sanofi Ischemic Heart Disease Drugs Major Product Offerings
7.10.4 Sanofi Ischemic Heart Disease Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Sanofi Key News & Latest Developments
8 Global Ischemic Heart Disease Drugs Production Capacity, Analysis
8.1 Global Ischemic Heart Disease Drugs Production Capacity, 2018-2029
8.2 Ischemic Heart Disease Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Ischemic Heart Disease Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Ischemic Heart Disease Drugs Supply Chain Analysis
10.1 Ischemic Heart Disease Drugs Industry Value Chain
10.2 Ischemic Heart Disease Drugs Upstream Market
10.3 Ischemic Heart Disease Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Ischemic Heart Disease Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Ischemic Heart Disease Drugs in Global Market
Table 2. Top Ischemic Heart Disease Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Ischemic Heart Disease Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Ischemic Heart Disease Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Ischemic Heart Disease Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Ischemic Heart Disease Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Ischemic Heart Disease Drugs Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Ischemic Heart Disease Drugs Product Type
Table 9. List of Global Tier 1 Ischemic Heart Disease Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Ischemic Heart Disease Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Ischemic Heart Disease Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Ischemic Heart Disease Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Ischemic Heart Disease Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Ischemic Heart Disease Drugs Sales (K Units), 2024-2029
Table 16. By Application – Global Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Ischemic Heart Disease Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Ischemic Heart Disease Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Ischemic Heart Disease Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Ischemic Heart Disease Drugs Sales (K Units), 2024-2029
Table 21. By Region – Global Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Ischemic Heart Disease Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Ischemic Heart Disease Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Ischemic Heart Disease Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Ischemic Heart Disease Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Ischemic Heart Disease Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Ischemic Heart Disease Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Ischemic Heart Disease Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Ischemic Heart Disease Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Ischemic Heart Disease Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Ischemic Heart Disease Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Ischemic Heart Disease Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Ischemic Heart Disease Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Ischemic Heart Disease Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Ischemic Heart Disease Drugs Sales, (K Units), 2024-2029
Table 46. AstraZeneca Company Summary
Table 47. AstraZeneca Ischemic Heart Disease Drugs Product Offerings
Table 48. AstraZeneca Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. AstraZeneca Key News & Latest Developments
Table 50. Actelion Company Summary
Table 51. Actelion Ischemic Heart Disease Drugs Product Offerings
Table 52. Actelion Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Actelion Key News & Latest Developments
Table 54. Bayer Company Summary
Table 55. Bayer Ischemic Heart Disease Drugs Product Offerings
Table 56. Bayer Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Bayer Key News & Latest Developments
Table 58. Boehringer Ingelheim Company Summary
Table 59. Boehringer Ingelheim Ischemic Heart Disease Drugs Product Offerings
Table 60. Boehringer Ingelheim Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Boehringer Ingelheim Key News & Latest Developments
Table 62. Bristol-Myers Squibb Company Summary
Table 63. Bristol-Myers Squibb Ischemic Heart Disease Drugs Product Offerings
Table 64. Bristol-Myers Squibb Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Bristol-Myers Squibb Key News & Latest Developments
Table 66. Baxter Company Summary
Table 67. Baxter Ischemic Heart Disease Drugs Product Offerings
Table 68. Baxter Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Baxter Key News & Latest Developments
Table 70. Eli Lilly and Company Company Summary
Table 71. Eli Lilly and Company Ischemic Heart Disease Drugs Product Offerings
Table 72. Eli Lilly and Company Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Eli Lilly and Company Key News & Latest Developments
Table 74. Novartis Company Summary
Table 75. Novartis Ischemic Heart Disease Drugs Product Offerings
Table 76. Novartis Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Novartis Key News & Latest Developments
Table 78. Pfizer Company Summary
Table 79. Pfizer Ischemic Heart Disease Drugs Product Offerings
Table 80. Pfizer Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Pfizer Key News & Latest Developments
Table 82. Sanofi Company Summary
Table 83. Sanofi Ischemic Heart Disease Drugs Product Offerings
Table 84. Sanofi Ischemic Heart Disease Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Sanofi Key News & Latest Developments
Table 86. Ischemic Heart Disease Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 87. Global Ischemic Heart Disease Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 88. Global Ischemic Heart Disease Drugs Production by Region, 2018-2023 (K Units)
Table 89. Global Ischemic Heart Disease Drugs Production by Region, 2024-2029 (K Units)
Table 90. Ischemic Heart Disease Drugs Market Opportunities & Trends in Global Market
Table 91. Ischemic Heart Disease Drugs Market Drivers in Global Market
Table 92. Ischemic Heart Disease Drugs Market Restraints in Global Market
Table 93. Ischemic Heart Disease Drugs Raw Materials
Table 94. Ischemic Heart Disease Drugs Raw Materials Suppliers in Global Market
Table 95. Typical Ischemic Heart Disease Drugs Downstream
Table 96. Ischemic Heart Disease Drugs Downstream Clients in Global Market
Table 97. Ischemic Heart Disease Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Ischemic Heart Disease Drugs Segment by Type in 2022
Figure 2. Ischemic Heart Disease Drugs Segment by Application in 2022
Figure 3. Global Ischemic Heart Disease Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Ischemic Heart Disease Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Ischemic Heart Disease Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Ischemic Heart Disease Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Ischemic Heart Disease Drugs Revenue in 2022
Figure 9. By Type - Global Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Ischemic Heart Disease Drugs Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Ischemic Heart Disease Drugs Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Ischemic Heart Disease Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
Figure 23. US Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
Figure 28. Germany Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
Figure 37. China Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Ischemic Heart Disease Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Ischemic Heart Disease Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Ischemic Heart Disease Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Ischemic Heart Disease Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Ischemic Heart Disease Drugs by Region, 2022 VS 2029
Figure 54. Ischemic Heart Disease Drugs Industry Value Chain
Figure 55. Marketing Channels

※参考情報

虚血性心疾患は、心臓の血流が不足することによって引き起こされる病状であり、主に冠動脈疾患が原因とされます。この疾患は心筋の酸素供給が不足し、結果として心筋の機能が低下することが特徴です。虚血性心疾患に対する治療薬は、主に心筋への血流を改善し、心臓の負担を軽減することを目的としています。

虚血性心疾患の治療薬は、一般にいくつかの異なるクラスに分類されます。第一に、抗血小板薬が挙げられます。これらの薬剤は血小板の凝集を抑制し、血栓の形成を防ぐ働きを持っています。アスピリンやクロピドグレルなどがこのカテゴリに含まれ、心筋梗塞や脳卒中の予防に広く用いられています。抗血小板薬の使用によって、冠動脈内の急性の閉塞を防ぎ、血流を維持することが期待されます。

次に、β遮断薬について説明します。この薬剤は、交感神経系の働きを抑えることで心拍数や血圧を低下させ、心臓の酸素需要を減少させる効果があります。心筋への負担を軽減し、虚血発作の頻度を減少させるため、心筋梗塞の予後改善にも寄与します。代表的なβ遮断薬にはメトプロロールやアモニウムがあり、心筋梗塞後の長期的な治療において必須の薬剤とされています。

さらに、ACE阻害薬も虚血性心疾患の治療において重要です。これらの薬剤は、アンジオテンシン変換酵素を阻害することによって血管を拡張し、心臓への負担を軽減します。心不全の治療にも用いられ、高血圧の管理にも寄与します。リシノプリルやエナラプリルなどがこのクラスの代表的な薬剤です。

また、カルシウム拮抗薬も虚血性心疾患の治療において使用されます。これらの薬剤は心臓の収縮力を低下させ、心筋の酸素要求を減少させることから、狭心症の治療に有効です。具体的にはベラパミルやジルチアゼムといった薬剤が用いられ、心筋の酸素供給と需要のバランスを調整する役割を果たします。

さらに、硝酸薬も虚血性心疾患の治療に用いられます。これらの薬剤は血管拡張作用があり、心筋への血流を増加させることで虚血を緩和します。舌下で使用されるニトログリセリンが有名で、急性の狭心症発作時に効果的です。

最近では、新しい治療法や薬剤も開発されています。例えば、ステロイド様の作用を持つ薬剤や新しい抗血栓薬、さらには心筋再生を目的とした細胞治療など、技術革新が進んでいます。これらは従来の治療薬の効果を補完し、さらなる治療効果を目指すものです。

虚血性心疾患の治療薬の選択は、患者の病状や併存症によって異なります。具体的には、心筋梗塞の既往歴、心不全の有無、高血圧や糖尿病の管理といった要素が考慮される必要があります。また、治療計画には生活習慣の改善やリハビリテーションも重要です。食事の見直しや定期的な運動、禁煙、ストレス管理は、薬物療法と併せて行うべきです。

加えて、仮想的な技術の進展により、個別化医療が進んでいます。患者の遺伝的背景やライフスタイルに基づいたオーダーメイドの治療が可能となり、最適な治療法を選択することができるようになっています。これにより、治療効果の向上と副作用の軽減が期待されています。

虚血性心疾患の治療薬は、心筋の酸素供給を改善しつつ、心疾患関連のリスクを低減するために設計されています。今後も新薬の開発や革新が進むことで、より良い治療戦略が確立されることが期待されています。患者にとって、安全かつ効率的な治療法が提供されることは、医療の質向上に大いに寄与するものと考えられています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 虚血性心疾患治療薬の世界市場見通し2023年-2029年(Ischemic Heart Disease Drugs Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

虚血性心疾患治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp